The six Delta platform for outcome-based contracting for pharmaceuticals

Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: δ3: reference-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: δ4: safety-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Pricing methods in outcome-based contracting: δ6: adherence-based pricing

(2020) Nimer S. Alkhatib et al.   JOURNAL OF MEDICAL ECONOMICS

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden

(2018) P. Frisk et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Value-Based Pricing for Drugs

(2018) Anna Kaltenboeck et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Outrageous prices of orphan drugs: a call for collaboration

(2018) Lucio Luzzatto et al.   LANCET

Sustainability and affordability of cancer drugs: a novel pricing model

(2018) Carin A. Uyl-de Groot et al.   Nature Reviews Clinical Oncology

The Early Awareness and Alert System in Sweden: History and Current Status

(2017) Irene Eriksson et al.   Frontiers in Pharmacology

Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?

(2016) Livio Garattini et al.   PHARMACOECONOMICS

Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer

(2016) Ana Clopes et al.   JOURNAL OF MEDICAL ECONOMICS

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

(2013) Louis P. Garrison et al.   VALUE IN HEALTH

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

(2010) Jakub Adamski et al.   BMC HEALTH SERVICES RESEARCH